Industry’s largest survey on serialization readiness throws up disparity30 Apr 2018
Global Drug Supply, Safety and Traceability Report reveals disparity in industry’s readiness to comply with track and trace regulations in the US and EU.
TraceLink has unveiled the second annual Global Drug Supply, Safety and Traceability (GDSST) Report, including results from 660 respondents across the pharmaceutical supply chain - the largest survey ever conducted on pharmaceutical track and trace.
The 65-page report highlights a massive gap in industry readiness for drug serialization, with only one-third of respondents stating that they are “very prepared” to comply with serialization deadlines in the US and EU. The in-depth analysis also reports that not one survey respondent has completed all of the fundamental steps for serialization compliance.
Key findings from the GDSST Report include the following:
“This year, serialization becomes a true reality for many pharmaceutical companies. As the leader in the market, we feel that TraceLink has a responsibility to provide insight into the state of serialization as it stands today, by leveraging our unique ability to reach the entire supply chain, from end-to-end, through our 266,000+ trade partner network,” said Shabbir Dahod, president and CEO of TraceLink.
“These survey results are startling. Despite goodwill efforts by industry and regulators to meet compliance on time, the industry is extremely behind in being ready for serialization. In 2018, as we reach the final hours of serialization in both the US and EU, the industry-wide lag in full serialization implementations remains a concern and emphasizes the criticality of trade partner connectivity within the supply chain.”
Accounting for the disparity
Not one of the EU FMD pharma respondents who said they were “very ready” for serialization were fully integrated with their CMOs, whereas 73% of CMOs stated they were connected with their brand owner customers. Pasi Kemppainen, management advisor, global serialization and traceability, Santen Pharmaceutical, was asked what he thought has caused this disparity.
"There are a few very practical causes for this disparity. First, the CMOs are comfortable in saying they are ready because their hardware, systems and software are in place and validated, and many are working with a small, selected pool of first mover pharma customers. The pharma companies, on the other hand, have to connect with a large number of CMOs and each will have a different approach to serialization catering to differing demands from their customers. This elongates and complicates connections unless they are all using a network approach. So there might be a technical readiness in place at the pharma side but the full roll-out with CMOs is still in early stages.
"Second, there may be differences in perception between departments; for example, site level operational teams will normally be ‘ready’ well in advance of teams working on data exchange projects in IT departments. If these departments are failing to communicate, they will not appreciate where the project is in terms of completion."
Third-party specialists vs in-house
Thirty percent of EU FMD pharma companies had already hired additional staff dedicated to serialization, compared with just 9% of Drug Supply Chain Security Act (DSCSA) companies at the same point last year. Regarding the question of whether pharma companies should look to third-party specialists to fill resource gaps or recruit in-house, Pasi Kemppainen answered: "Pharma companies should, and in most cases are looking to third-parties to fill gaps in resource and knowledge. It’s more of a necessity for the EU regulation as the FMD requirements are more complex than DSCSA — there’s one, absolute deadline for all stakeholders involved and the regulation is more ambitious in terms of what needs to be implemented with a shorter timetable.
The European market is also inherently more complicated due to the freedom each country has in terms of interpreting the FDM requirements, especially the artwork requirements. There might be nuanced differences between the countries and therefore, different requirements for MAH’s implementation on all levels of serialization and traceability, and especially on the supply network integration, depending on the country and stakeholder they are shipping products to.
Pasi Kemppainen will be presenting at FutureLink Munich, 5-7 June 2018.
TraceLink partnered with independent research firm, Penn Schoen Berland, to conduct the survey and produce the report analysis.
BMS and Celgene merge to create premier innovative biopharma company
3 Jan 2019
Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.Read more
An increased risk of a hard or ‘no deal Brexit?
24 Dec 2018
A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.Read more
One month on: medical cannabis is still taboo despite change in law
11 Dec 2018
Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.Read more
EU FMD - time is running out!
13 Nov 2018
Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.Read more
Proprietary nasal delivery formulation of diazepam reaches NDA
7 Nov 2018
The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.Read more
DSCSA one-month countdown!
30 Oct 2018
With only a month to go, it really is too late to start trying to develop an in-house solution.Read more
Global pharma set for strong year
23 Oct 2018
Eight of the top ten pharma nations reporting improving market conditions.Read more
Generics companies to move away from "little white pills"
14 Oct 2018
Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.Read more
CMOs to benefit from double digit approvals for ADCs in the next 3 years
9 Oct 2018
Therapeutic ADC market expected to reach $4 billion by 2023.Read more
Movement on the market reflected at CPhI Worldwide 2018
3 Oct 2018
Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation